6th Global College of Neuroprotection and Neuroregeneration, Annual Meeting

Abstract

The 6th Global College of Neuroprotection and Neuroregeneration (GCNN) and 5th Society for Study on Neuroplasticity and Neuroregeneration (SSNN) conference was held jointly in the Hilton Hotel, Vienna, Austria, 1–4 March 2009. This was the second annual joint conference of the two societies and it was highly successful from a scientific point of view, as it saw a gathering of the top basic and clinical scientists whose research is currently at the cutting edge of neuroscience. This conference saw 86 invited lectures from carefully selected leading scientists from around the world, along with 56 posters of young scientists researching of a focal theme. Over the 3 days, in 32 sessions, new developments in neuroprotection and new ways to enhance neuroregeneration were discussed intensively among more than 600 delegates. In addition, approximately 40 representatives of drug companies, five representatives from scientific publishers and 14 representatives from scientific instruments and supplies-related industries also actively participated in this huge neuroscience event. The GCNN and SSNN conference achieved a new milestone in scientific success in Vienna and established an excellent new working collaboration among the participants in a pleasant, enriched environment with several social gatherings.

Keywords::

• blood–brain barrier
• brain damage
• drug treatment
• neurodegeneration
• neuroprotection
• neuroregeneration
• neurotoxicity

Financial & competing interests disclosure

The views expressed in this report are exclusively the opinion of Hari Shanker Sharma based on current scientific literature and available knowledge so far. These views in no way represent the official opinion of any organization mentioned or Uppsala University. Hari S Sharma’s research on Neuroproetction and Neuroregeneration is partly supported by Swedish Medical Research Council (2710); Göran Gustafsson Foundation, Stockholm, Sweden; European Office of Aerospace Research and Development (EOARD), London; United States Air Force Research Laboratory, Wright Patterson Air Force Base, Dayton, OH, USA; National Institute on Drug Abuse (NIDA), Distinguished International Scientists Collaboration Award (DISCA) Program, NIH, Baltimore, MD, USA; US FDA, National Centre for Toxicological Research (NCTR), Jefferson, AR, USA; Astra Zeneca, Mölndal, Sweden; Uppsala University, Uppsala, Sweden; University Hospital, Uppsala University, Uppsala, Sweden; Acure Pharma, Uppsala, Sweden; Global College of Neuroprotection and Neuroregeneration (GCNN), London, UK; Ebewe Pharma, Austria; Society for Study on Neuroplasticity and Neuroregeneration (SSNN), Cluj-Napoca, Romania; Department of Science & Technology, Government of India, New Delhi, India; University Grants Commission, New Delhi, Government of India and Medical Research Council; and the New Delhi, Government of India. However, Hari Shanker Sharma has no conflict of interest with any organization or the pharmaceutical companies listed above for his research or his association with Uppsala University. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.